CEFEPIME HYDROCHLORIDE

Post-LOE

cefepime hydrochloride

Molecular Devices

ANDAINJECTIONINJECTABLE

Approved

Dec 2010

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CEFEPIME HYDROCHLORIDE (cefepime hydrochloride) by Molecular Devices is [ see microbiology ( ]. Approved for the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae, including cases associated with concurrent bacteremia, pseudomonas aeruginosa and 15 more indications. First approved in 2010.

Drug data last refreshed Yesterday

Mechanism of Action

[ See Microbiology ( ].

Indications (18)

the treatment of pneumonia (moderate to severe) caused by susceptible strains of Streptococcus pneumoniae including cases associated with concurrent bacteremia

Worked on CEFEPIME HYDROCHLORIDE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.